Operating Segments (Tables)

3 Months Ended

Mar. 31, 2024

Operating Segments

Schedule of operating segments

	Three Months Ended
	March 31,
	2024		2023
Revenues
Specialized BioTherapeutics	$	117,029	$	155,365
Public Health Solutions		—		101,813
Total	$	117,029	$	257,178
Income (loss) from Operations
Specialized BioTherapeutics	$	(860,604)	$	(910,377)
Public Health Solutions		(45,997)		427
Corporate		(1,210,490)		(1,240,739)
Total	$	(2,117,091)	$	(2,150,689)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	953	$	1,071
Public Health Solutions		159		178
Corporate		476		536
Total	$	1,588	$	1,785
Other (Expense) Income, Net
Specialized BioTherapeutics	$	7,540	$	6,082
Corporate		194,224		(62,699)
Total	$	201,764	$	(56,617)
Share-Based Compensation
Specialized BioTherapeutics	$	20,672	$	27,427
Public Health Solutions		588		994
Corporate		38,701		45,213
Total	$	59,961	$	73,634

	As of		As of
	March 31,		December 31,
	2024		2023
Identifiable Assets
Specialized BioTherapeutics	$	301,709	$	272,099
Public Health Solutions		120,475		3,976
Corporate		7,636,201		9,521,251
Total	$	8,058,385	$	9,797,326